Odimma Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 7

Odimma Therapeutics General Information

Description

Developer of an immunotherapy drug designed for personalized immunotherapy to treat cancer. The company's platform combines three specific immune players that synergize with the immune system when injected into patients to induce and amplify an immune response and cellular immune response against specific tumour markers, enabling patients to cure tumors with fewer side effects and support the cancer treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • ISIS, 8 Allée Gaspard Monge
  • 67000 Strasbourg
  • France
+33 0
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • ISIS, 8 Allée Gaspard Monge
  • 67000 Strasbourg
  • France
+33 0

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Odimma Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Accelerator/Incubator Completed Clinical Trials - Phase 1
6. Later Stage VC 11-Jul-2023 Completed Clinical Trials - Phase 1
5. Seed Round 20-Oct-2021 Completed Clinical Trials - Phase 1
4. Seed Round 18-Dec-2019 Completed Pre-Clinical Trials
3. Grant 18-Dec-2019 Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Odimma Therapeutics’s complete valuation and funding history, request access »

Odimma Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ABSA P2022
P Shares
P Shares 80,646 $0.414654 $6.77 $6.77 1x $6.77 18.12%
To view Odimma Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Odimma Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immunotherapy drug designed for personalized immunotherapy to treat cancer. The company's platform combi
Biotechnology
Strasbourg, France
4 As of 2026

Geneva, Switzerland
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Odimma Therapeutics Competitors (84)

One of Odimma Therapeutics’s 84 competitors is Amal Therapeutics, a Formerly VC-backed company based in Geneva, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amal Therapeutics Formerly VC-backed Geneva, Switzerland
AnTolRx Formerly VC-backed Cambridge, MA
MonTa BioSciences Venture Capital-Backed Lyngby, Denmark
Repertoire Immune Medicines Venture Capital-Backed Cambridge, MA
Immunophotonics Private Equity-Backed Saint Louis, MO
You’re viewing 5 of 84 competitors. Get the full list »

Odimma Therapeutics Patents

Odimma Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026154072-A1 Enveloped virus for transfection of exogenous nucleic acids Pending 17-Jan-2025
FR-3171450-A1 Enveloped virus for transfection of exogenous nucleic acids. Pending 17-Jan-2025
FR-3160186-A1 Non-viral vector for enhanced transcription Pending 13-Mar-2024
WO-2025190971-A1 Non-viral vector for enhanced transcription Pending 13-Mar-2024 C12N15/85

Odimma Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Odimma Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alsace Business Angels Angel Group Minority
Angels Santé Angel Group Minority
Bpifrance Sovereign Wealth Fund Minority
Capital Grand Est PE/Buyout Minority
Matwin Accelerator/Incubator
You’re viewing 5 of 7 investors. Get the full list »

Odimma Therapeutics FAQs

  • When was Odimma Therapeutics founded?

    Odimma Therapeutics was founded in 2017.

  • Where is Odimma Therapeutics headquartered?

    Odimma Therapeutics is headquartered in Strasbourg, France.

  • What is the size of Odimma Therapeutics?

    Odimma Therapeutics has 4 total employees.

  • What industry is Odimma Therapeutics in?

    Odimma Therapeutics’s primary industry is Biotechnology.

  • Is Odimma Therapeutics a private or public company?

    Odimma Therapeutics is a Private company.

  • What is Odimma Therapeutics’s current revenue?

    The current revenue for Odimma Therapeutics is .

  • How much funding has Odimma Therapeutics raised over time?

    Odimma Therapeutics has raised $3.28M.

  • Who are Odimma Therapeutics’s investors?

    Alsace Business Angels, Angels Santé, Bpifrance, Capital Grand Est, and Matwin are 5 of 7 investors who have invested in Odimma Therapeutics.

  • Who are Odimma Therapeutics’s competitors?

    Amal Therapeutics, AnTolRx, MonTa BioSciences, Repertoire Immune Medicines, and Immunophotonics are some of the 84 competitors of Odimma Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process